These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 3100429)

  • 1. [Selection of resistant variants by broad spectrum beta-lactam antibiotics: to what extent is there cross resistance between imipenem and other beta-lactam antibiotics?].
    Kahan F; Kropp H
    Immun Infekt; 1986 Nov; 14(6):232-5. PubMed ID: 3100429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Emergence of resistance to beta-lactam antibiotics in Pseudomonas aeruginosa during treatment with new beta-lactams.
    Lerner SA; Quinn JP
    Chemioterapia; 1985 Feb; 4(1):95-101. PubMed ID: 3921267
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Characterization of imipenem resistance in Pseudomonas aeruginosa: decreased phenotypic expression of outer membrane proteins D1 and D2].
    Cullmann W; Büscher KH; Opferkuch W
    Immun Infekt; 1986 Nov; 14(6):227-9. PubMed ID: 3100427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emergence of cross-resistance to imipenem and other beta-lactam antibiotics in Pseudomonas aeruginosa during therapy.
    Pagani L; Landini P; Luzzaro F; Debiaggi M; Romero E
    Microbiologica; 1990 Jan; 13(1):43-53. PubMed ID: 2155376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibacterial activity of imipenem: the first thienamycin antibiotic.
    Kropp H; Gerckens L; Sundelof JG; Kahan FM
    Rev Infect Dis; 1985; 7 Suppl 3():S389-410. PubMed ID: 3931196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of ertapenem use on the susceptibility of Pseudomonas aeruginosa to imipenem: a hospital case study.
    Lima AL; Oliveira PR; Paula AP; Dal-Paz K; Rossi F; Zumiotti AV
    Infect Control Hosp Epidemiol; 2009 May; 30(5):487-90. PubMed ID: 19335227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps.
    Ong CT; Tessier PR; Li C; Nightingale CH; Nicolau DP
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):153-61. PubMed ID: 16930925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Development of resistance in imipenem therapy in Pseudomonas aeruginosa].
    Krech T; Naumann P
    Immun Infekt; 1986 Nov; 14(6):224-6. PubMed ID: 3100426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Imipenem resistance in Pseudomonas aeruginosa].
    Bauernfeind A; Hörl G
    Immun Infekt; 1986 Nov; 14(6):221-4. PubMed ID: 3100425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in the development of beta-lactam antibiotics.
    Neu HC
    Scand J Infect Dis Suppl; 1984; 42():7-16. PubMed ID: 6597563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of beta-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa.
    Carsenti-Etesse H; Cavallo JD; Roger PM; Ziha-Zarifi I; Plesiat P; Garrabe E; Dellamonica P
    Chirurgia (Bucur); 2002; 97(2):151-9. PubMed ID: 12731225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imipenem resistance in Pseudomonas aeruginosa resulting from diminished expression of an outer membrane protein.
    Büscher KH; Cullmann W; Dick W; Opferkuch W
    Antimicrob Agents Chemother; 1987 May; 31(5):703-8. PubMed ID: 3111361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility of nosocomial Pseudomonas aeruginosa, enterobacteriaceae, and staphylococci to ciprofloxacin and ten other broad-spectrum antibiotics.
    Weinstein RA; Nathan C; Delzell D; Kabins SA
    Chemioterapia; 1987 Oct; 6(5):315-8. PubMed ID: 3123078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of imipenem against Pseudomonas and Bacteroides species.
    Williams JD
    Rev Infect Dis; 1985; 7 Suppl 3():S411-6. PubMed ID: 3931197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreases of the susceptibility to low molecular weight beta-lactam antibiotics in imipenem-resistant Pseudomonas aeruginosa mutants: role of outer membrane protein D2 in their diffusion.
    Gotoh N; Nishino T
    J Antimicrob Chemother; 1990 Feb; 25(2):191-8. PubMed ID: 2109748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imipenem: the first thienamycin antibiotic.
    Williams RJ
    Postgrad Med J; 1986; 62 Suppl 2():75-7. PubMed ID: 3118345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Resistance caused by hyperproduction of chromosomal beta-lactamase in Pseudomonas aeruginosa].
    Tirado M; Hermida M; Reig R; Esteva C; Vidal R; Roy C
    Enferm Infecc Microbiol Clin; 1989 Dec; 7(10):530-4. PubMed ID: 2518765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial.
    Calandra GB; Hesney M; Brown KR
    Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antibiotic susceptibility rates and beta-lactam resistance mechanisms of Pseudomonas aeruginosa strains].
    Aktaş Z; Satana D; Kayacan C; Can B; Gönüllü N; Küçükbasmacı O
    Mikrobiyol Bul; 2012 Jul; 46(3):386-97. PubMed ID: 22951651
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.